EPIDEMIOLOGIA, KLASYFIKACJA ORAZ DIAGNOSTYKA CZYNNYCH I NIECZYNNYCH HORMONALNIE GRUCZOLAKÓW PRZYSADKI

Karolina Nowakowska

Bibliografia

1.Lloyd R.V., Kovacs K., Young Jr. W.F., Farell W.E., Asa S.L., Trouillas J. i wsp. Pituitary tumours. W: Pathobiology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumour. DeLellis RA, Lloyd RV, Heitz PU, Eng C. (red.), IARD Press Lyon, 2004, 10-39.

2. Scheithauer B.W., Gaffey T.A., Lloyd R.V, Sebo T.J., Kovacs K. , Horvath E. i wsp. Pathobiology of Pituitary Adenomas and Carcinomas. Neurosurgery. 2006, 59(2), 341-353.

3.  Salehi F., Vidal S., Horvath E., Kovacs K., Scheithauer BW. Tumors in the Adenohypophysis. Chapter 3. LLC. 2010, 73-89.  

4.  Saeger W. Pituitary tumors. Prognostic Indicators. Endocrine 2005, 28, 57-66.

5.  Daems T., Verhelst J., Michotte A., Abrams P., Ridder D., Abs R.. Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 2009, 12, 80-86.

6.  Pizarro C.B., Oliveira M.C., Coutinho L.B., Ferreira N.P. Measurment of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res. 2004, 37(2), 235-243.

7.  Righi A., Agati P., Sisto A., Frank G., Faustini M.i wsp. A classification tree approach for pituitary adenomas. Human Pathol. 2012, 43(10), 1627-1637.

8.  Hentschel SJ., McCutcheon IE., Moore W., Durity FA. P53 and MIB-1 Immunohistochemistry as Predictors of the Clinical Behavior of Nonfunctioning Pituitary Adenomas. Can J Neurol Sci. 2003,  30(3), 215-219.

9.  Lloyd R.V., Scheithauer B.W., Horvath E., Kovacs K. Tumors of the Pituitary Gland. LLC. 2009, 27-35.

10.  Maksymowicz M., Olszewski W.T., Przydatność mikroskopii elektronowej w diagnostyce gruczolaków przysadki. Folia Medica Lodziensia, 2010, 37/1, 151-173.

11.  Kontogergous G. Innovations and controversies in the WHO classification of pituitary adenomas. Acta Neuropathol. 2006, 111(1), 73-75.

12.  Mastronardi L., Guiducci A., Puzzilli F., Maira G. Anterior pituitary adenomas in patients aged more than 65 years: analysis of growth fraction (using the MIB-1 monoclonal antibody) and of clinical features in comparision to younger patients. Clin Neurol Neurosurg. 2002, 104(1), 44-48.

13. Rijn S.J., Grinwis G.C.M., Penning L.C., Meij B.P. Expression of Ki-67, PCNA, and p27kip1 in canine pituitary corticotroph adenomas. Dom Anim Endocrinol. 2010, 38(4), 244-252.

14. Andrioli M., Giraldi F., Losa M., Terreni M., Invitti C. i wsp. Cushing’s disease due to double pituitary ACTH-secreting adenomas: the first case report. Endocr J. 2010, 57(9), 833-837.

15. Kleinschmidt-DeMasters B.K. Subtyping does matter in pituitary adenomas. Acta Neuropathol. 2006, 111(1), 84-85.

16. Dembińska-Kieć A., Naskalski J.W. (red.). Diagnostyka laboratoryjna z elementami biochemii klinicznej. Diagnostyka laboratoryjna chorób gruczołów wydzielania wewnętrznego. Elsevier, 2010, 769-792.

17. Pawlikowski M., Kuta J., Fuss- Chmielewska J., Winczyk K. „Silent” somatotropinoma. Endokrynol Pol. 2012, 63(2), 88-91.

18. Maksymowicz M. Ocena przydatności mikroskopii elektronowej i immunocytochemii na poziomie ultrastrukturalnym w diagnostyce i klasyfikacji gruczolaków przysadki. 2002. Praca doktorska. Pomorski Uniwersytet Medyczny w Szczecinie.

19. Horvath E., Kovacs K., Smyth H.S., Cusimano M., Singer B. Silent Adenoma Subtype 3 of the Pituitary- Immunohistochemical and ultrastructural Classification: A Review of 29 Cases. Ultrastruct Pathol. 2005 , 29(6), 511-524 .

20. Cho H.Y., Cho S.W., Kim S.W., Park K.S., Kim S.Y. Sileni corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 2010, 72(5), 648-653.

21. Dubois S., Guyetant S., Menei P., Rodien P., Illouz F. i wsp. Revelance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur. J. Endocrinol. 2007, 157(2), 141-147.

22. Yamada S., Ohyama K., Taguchi M., Takeshita A., Morita K. i wsp. A study of the correlation between morphological findings and biological activities in clinically nonfunctionating pituitary adenomas. Neurosurgery. 2007, 61(3), 580-584.

23. Schreiber S., Saeger W., Ludecke D.K. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary. 1999, 1(3-4), 213-220.

24. Paek K., Kim S.H., Song S.H., Choi S.W. i wsp. Clinical Significance of Ki-67 Labelling Index in Pituitary Macroadenoma. J Korean Med Sci. 2005, 20(3), 489-494.

25. Yamada S., Ohyama K., Taguchi M., Takeshita A., Morita K., Takano K., Sano T. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery. 2007, 61(3), 580-584.

26. Mastronardi L., Guidicci A., Puzzilli F. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer. 2001, 1, 12.

27. Mete O., Ezzat S., Asa S.L. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 2012, 49(2), R69-R78.

28. Rugerri M., Costa G., Simone A., Campenni A., Sindon A., Ieni A. i wsp. Cell proliferation parameters and apoptosis indices in pituitary macroadenomas. J Endocrinol Invest. 2012, 35(5), 473-478.

29. Ogawa Y., Ikeda H., Tominaga T. Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labelling of more than 3%. J Endocrinol Invest. 2009, 32(7), 581-584.